4-phenylbutyric acid has been researched along with Tauopathies in 3 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Tauopathies: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human neurodegenerative tauopathies exhibit pathological tau aggregates in the brain along with diverse clinical features including cognitive and motor dysfunction." | 1.43 | Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. ( Bondulich, MK; Brion, JP; Guo, T; Hanger, DP; Hortobagyi, T; Manion, J; Meehan, C; Mitchell, JC; Noble, W; Rodriguez Martin, T; Stygelbout, V; Yankova, N, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondulich, MK | 1 |
| Guo, T | 1 |
| Meehan, C | 1 |
| Manion, J | 1 |
| Rodriguez Martin, T | 1 |
| Mitchell, JC | 1 |
| Hortobagyi, T | 1 |
| Yankova, N | 1 |
| Stygelbout, V | 1 |
| Brion, JP | 1 |
| Noble, W | 1 |
| Hanger, DP | 1 |
| Ricobaraza, A | 1 |
| Cuadrado-Tejedor, M | 1 |
| Pérez-Mediavilla, A | 1 |
| Frechilla, D | 1 |
| Del Río, J | 1 |
| García-Osta, A | 1 |
| Inden, M | 1 |
| Kitamura, Y | 1 |
| Takeuchi, H | 1 |
| Yanagida, T | 1 |
| Takata, K | 1 |
| Kobayashi, Y | 1 |
| Taniguchi, T | 1 |
| Yoshimoto, K | 1 |
| Kaneko, M | 1 |
| Okuma, Y | 1 |
| Taira, T | 1 |
| Ariga, H | 1 |
| Shimohama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS[NCT04987671] | Phase 1/Phase 2 | 14 participants (Anticipated) | Interventional | 2021-08-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for 4-phenylbutyric acid and Tauopathies
| Article | Year |
|---|---|
Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Disease Models, Animal; Female; Humans; Male; Mice | 2016 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2009 |
Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.
Topics: alpha-Synuclein; Animals; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Endopl | 2007 |